Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells

Blood. 2008 Aug 15;112(4):1515-21. doi: 10.1182/blood-2007-11-125542. Epub 2008 Apr 14.

Abstract

Extracorporeal photopheresis (ECP), a technique that exposes isolated white blood cells to photoactivatable 8-methoxypsoralen and ultraviolet A radiation, is used clinically to treat cutaneous T-cell lymphoma and immune-mediated diseases such as graft-versus-host disease (GVHD). ECP is thought to control these diseases in part through direct induction of lymphocyte apoptosis, but its effects on the immune system beyond apoptosis remain poorly characterized. We have developed a novel method for incorporating ECP treatment into well-established and clinically relevant murine models of GVHD to examine its effects during an ongoing immune response. We demonstrate that the transfer of cells treated with ECP reverses established GVHD by increasing donor regulatory T cells and indirectly reducing the number of donor effector lymphocytes that themselves had never been exposed to psoralen and ultraviolet A radiation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Marrow Transplantation / adverse effects
  • Disease Models, Animal
  • Female
  • Graft vs Host Disease / therapy*
  • Lymphocyte Count
  • Mice
  • Photopheresis*
  • Survival Rate
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / radiation effects
  • T-Lymphocyte Subsets / transplantation
  • T-Lymphocytes, Regulatory / transplantation*
  • Transplantation, Homologous